DE60130661T2 - Verwendung der 13-cis retinsäure zur behandlung von emphysemen - Google Patents

Verwendung der 13-cis retinsäure zur behandlung von emphysemen Download PDF

Info

Publication number
DE60130661T2
DE60130661T2 DE60130661T DE60130661T DE60130661T2 DE 60130661 T2 DE60130661 T2 DE 60130661T2 DE 60130661 T DE60130661 T DE 60130661T DE 60130661 T DE60130661 T DE 60130661T DE 60130661 T2 DE60130661 T2 DE 60130661T2
Authority
DE
Germany
Prior art keywords
retinoic acid
cis
emphysema
treatment
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60130661T
Other languages
German (de)
English (en)
Other versions
DE60130661D1 (de
Inventor
Paula Nanette Half Moon Bay BELLONI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE60130661D1 publication Critical patent/DE60130661D1/de
Application granted granted Critical
Publication of DE60130661T2 publication Critical patent/DE60130661T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60130661T 2000-08-02 2001-07-23 Verwendung der 13-cis retinsäure zur behandlung von emphysemen Expired - Fee Related DE60130661T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/631,151 US6339107B1 (en) 2000-08-02 2000-08-02 Methods for treatment of Emphysema using 13-cis retinoic acid
US631151 2000-08-02
PCT/EP2001/008484 WO2002009679A2 (en) 2000-08-02 2001-07-23 Use of 13-cis retinoic acid for the treatment of emphysema

Publications (2)

Publication Number Publication Date
DE60130661D1 DE60130661D1 (de) 2007-11-08
DE60130661T2 true DE60130661T2 (de) 2008-07-03

Family

ID=24529991

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60130661T Expired - Fee Related DE60130661T2 (de) 2000-08-02 2001-07-23 Verwendung der 13-cis retinsäure zur behandlung von emphysemen

Country Status (7)

Country Link
US (2) US6339107B1 (enExample)
EP (1) EP1307187B1 (enExample)
JP (1) JP2004505036A (enExample)
AU (1) AU2001289726A1 (enExample)
DE (1) DE60130661T2 (enExample)
ES (1) ES2292620T3 (enExample)
WO (1) WO2002009679A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6339107B1 (en) * 2000-08-02 2002-01-15 Syntex (U.S.A.) Llc Methods for treatment of Emphysema using 13-cis retinoic acid
US7891578B2 (en) * 2001-03-22 2011-02-22 Battelle Memorial Institute Liquid formations for electrohydrodymanic spraying containing polymer and suspended particles
JP2005507934A (ja) * 2001-10-30 2005-03-24 ネクター セラピューティックス エイエル，コーポレイション レチノイン酸の水溶性ポリマー結合体
US20030185762A1 (en) * 2002-03-22 2003-10-02 Cowan Siu Man L. Highly aqueous liquid carrier formulations
AU2003270414A1 (en) * 2002-09-06 2004-03-29 Oregon Health And Science University Effect of vitamin a gel on paranasal sinus mucosal regeneration
JPWO2006025395A1 (ja) * 2004-08-31 2008-05-08 慶彦 清水 キャリアフリーの細胞増殖因子を用いた慢性閉塞性肺疾患に対する医薬および処置システム
WO2006079209A1 (en) * 2005-01-26 2006-08-03 The University Of British Columbia Pulmonary compositions comprising a vitamin a compound and a surfactant and uses thereof
WO2007104030A1 (en) * 2006-03-08 2007-09-13 Kinemed, Inc. Retinoids and related compounds for the treatment of neuroinflammatory conditions, diseases and disorders
US20070254858A1 (en) * 2006-04-27 2007-11-01 Cronk Peter J Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects
US20070254025A1 (en) * 2006-04-27 2007-11-01 Cronk Peter J Oral contraceptive and acne medication combination and treatment of acne with reduced side effects
US10022348B2 (en) 2009-05-20 2018-07-17 Sun Pharmaceutical Industries Limited Topical solution of isotretinoin
CA2762391C (en) * 2009-05-20 2017-02-07 Ranbaxy Laboratories Limited Liquid dosage forms of isotretinoin
CN102458362A (zh) 2009-05-20 2012-05-16 兰贝克赛实验室有限公司 外用类维生素a溶液
MX2015008333A (es) * 2012-12-27 2015-11-09 Microdose Therapeutx Inc Metodos y composiciones para la administracion de oxibutinina.
WO2017043616A1 (ja) * 2015-09-10 2017-03-16 国立大学法人 岡山大学 炎症性呼吸器疾患の予防又は治療用医薬組成物
CN113372368B (zh) 2020-03-09 2022-04-12 苏州爱科百发生物医药技术有限公司 一种弹性蛋白酶抑制剂前药及其用途
JP2025508115A (ja) * 2022-03-08 2025-03-21 マスタリー バイオテック カンパニー，リミテッド レチノイン酸および炭水化物を含む医薬組成物ならびにその使用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB334585A (en) * 1929-06-06 1930-09-08 British Glues And Chemicals Lt Improvements in or relating to the separation of solids from liquids
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
IL90069A (en) 1988-04-26 1994-04-12 Us Health The use of 31 cysts of retinoic acid in the preparation of a drug for the treatment of congenital conjunctivitis
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
GB9116909D0 (en) * 1991-08-06 1991-09-18 Salford Ultrafine Chem & Res Morphine derivatives
TW272187B (enExample) 1992-05-20 1996-03-11 Hoffmann La Roche
GB9225098D0 (en) 1992-12-01 1993-01-20 Coffee Ronald A Charged droplet spray mixer
GB9226717D0 (en) 1992-12-22 1993-02-17 Coffee Ronald A Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories
GB9406255D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9406171D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9410658D0 (en) 1994-05-27 1994-07-13 Electrosols Ltd Dispensing device
DE69605025T2 (de) 1995-03-14 2000-07-20 Siemens Ag Ultraschallzerstäuber mit abnehmbarer präzisionsdosiereinheit
IL117474A (en) 1995-03-14 2001-04-30 Siemens Ag Removable precise dosing unit containing inhaled drugs for a hearing aid device
US6515022B2 (en) * 1996-04-19 2003-02-04 Sloan-Kettering Institute For Cancer Research Use of inhaled retinoids in the treatment of lung diseases
WO1997039745A1 (en) 1996-04-19 1997-10-30 Sloan-Kettering Institute For Cancer Research Use of inhaled retinoids in the prevention of cancer
US5998486A (en) 1997-07-08 1999-12-07 Georgetown University School Of Medicine Treatment of emphysema with retinoic acid or other retinoids by inducing formation of gas-exchange units (alveoli)
US5954047A (en) 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
EP1066074A1 (en) 1998-03-16 2001-01-10 Inhale Therapeutic Systems, Inc. Aerosolized active agent delivery
US6339107B1 (en) * 2000-08-02 2002-01-15 Syntex (U.S.A.) Llc Methods for treatment of Emphysema using 13-cis retinoic acid

Also Published As

Publication number Publication date
JP2004505036A (ja) 2004-02-19
WO2002009679A2 (en) 2002-02-07
US20020049252A1 (en) 2002-04-25
AU2001289726A1 (en) 2002-02-13
EP1307187B1 (en) 2007-09-26
DE60130661D1 (de) 2007-11-08
EP1307187A2 (en) 2003-05-07
ES2292620T3 (es) 2008-03-16
US6339107B1 (en) 2002-01-15
US6794416B2 (en) 2004-09-21
WO2002009679A3 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
DE60130661T2 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE69332240T2 (de) Ultrafeines pulver zur inhalation und dessen herstellung
DE69834955T2 (de) Neue Verwendung von Budesonide und Formoterol
DE3815221C2 (de) Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
DE69629591T2 (de) Formulierung zur intranasalen verabreichung
DE69428268T2 (de) Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma
DE69930259T2 (de) Zusammensetzungen zur anwendung von entzündungshemmenden, insbesondere antiseptischen und/oder wundheilenden wirkstoffen im oberen atemwegtrakt und/oder ohr
DE69938390T2 (de) Verwendung einer zusammensetzung welche formoterol und budesonide enthält, zur verhinderung oder behandlung eines akuten astmazustandes
DE69631786T3 (de) Über die lungen verabreichbares trockenpulver alpha 1-antitrypsin
EP1263422B1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE68923697T3 (de) Nasale verabreichung von benzodiazepinhypnotika.
DE3686025T2 (de) Verfahren und system zum einatmen von liposomen.
EP2110126B9 (de) Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich
DE60026855T2 (de) Synergistische kombination von roflumilast und salmeterol
DE69807420T2 (de) Pharmazeutische aerosolzusammensetzung
DE69431433T2 (de) Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen
DE69530519T2 (de) Parathyroidhormon pth enthaltende therapeutische zubereitung zur inhalation
DE69306379T2 (de) Inhalierbare arzneimittel
DE69327432T2 (de) Heilmittel für wunden und hämorrhoiden
EP1216046B1 (de) Neue kombination von loteprednol und antihistaminika
WO2000023065A2 (de) Lagerfähiges wirkstoffkonzentrat mit formoterol
EP1526870B1 (de) Kombination von loteprednoletabonat und dfho zur behandlung von atemwegserkrankungen, allergischen erkrankungen, asthma und copd
RU2257383C2 (ru) Лечение эмфиземы с помощью ретиноидных агонистов (rar), обладающих избирательным действием
DE112019000683T5 (de) Intranasale epinephrin-formulierungen und verfahren zur behandlung von erkrankungen
DE60315426T2 (de) Pharmazeutische zusammensetzung enthaltend einen pde4 oder pde3/4 inhibitor und eine histaminrezeptorantagonisten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee